1. Home
  2. AWX vs SKYE Comparison

AWX vs SKYE Comparison

Compare AWX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AWX

Avalon Holdings Corporation

N/A

Current Price

$2.56

Market Cap

10.8M

Sector

Utilities

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$2.04

Market Cap

9.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AWX
SKYE
Founded
1998
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8M
9.0M
IPO Year
1998
2013

Fundamental Metrics

Financial Performance
Metric
AWX
SKYE
Price
$2.56
$2.04
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
8.9K
516.4K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$53,090,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.14
N/A
52 Week Low
$2.43
$0.26
52 Week High
$5.43
$4.99

Technical Indicators

Market Signals
Indicator
AWX
SKYE
Relative Strength Index (RSI) 41.91 68.24
Support Level $2.47 $0.66
Resistance Level $2.56 $2.32
Average True Range (ATR) 0.06 0.17
MACD -0.01 0.02
Stochastic Oscillator 5.00 65.57

Price Performance

Historical Comparison
AWX
SKYE

About AWX Avalon Holdings Corporation

Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment, which is the key revenue driver, provides hazardous and non-hazardous brokerage and management services to industrial, commercial, municipal, and governmental customers, captive landfill management for an industrial customer, and saltwater injection well operations. Its Golf and related operations segment consists of four golf courses and associated clubhouses, which provide dining and banquet facilities, a hotel which provides lodging and resort-related amenities.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: